Get the Daily Brief
Latest Biotech News
Johnson & Johnson’s Inlexzo Gains FDA Approval for Bladder Cancer Treatment
The U.S. Food and Drug Administration approved Johnson & Johnson’s drug-device combination system, Inlexzo, for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive...
LB Pharmaceuticals Breaks Biotech IPO Drought with $285M Offering
LB Pharmaceuticals raised $285 million through an upsized IPO on Nasdaq, signalling renewed investor interest in biotech after a seven-month hiatus. The company plans to use the proceeds to...
Revolution Medicines Advances RAS Blocker daraxonrasib Towards Phase III in Pancreatic Cancer
Revolution Medicines announced positive Phase I results for daraxonrasib, a multi-selective RAS inhibitor targeting pancreatic ductal adenocarcinoma, leading to plans for a global Phase III...
AI Models Mirror Experimental Science Revealing New Bacterial Gene Transfer Mechanism
Imperial College London researchers discovered that ‘‘pirate’’ phages hijack tails from unrelated viruses to infect new bacterial species, expanding antimicrobial resistance spread through...
CRISPR-Cas9 Base Editing Shows Promise in Treating Rare Vascular Disease in Mice
Researchers at Mass General Brigham engineered and screened base editors for precise correction of a single mutation in the ACTA2 gene responsible for multisystemic smooth muscle dysfunction...
Immunotherapy Innovation: ENPP1 Inhibitor STF-1623 Activates Innate Immune Response in Tumors
A new immunotherapy candidate, STF-1623, developed by Stanford and Arc Institute researchers, inhibits ENPP1 to prevent degradation of cGAMP, a molecule activating the STING pathway in innate...
Sapio Sciences and Ultima Genomics Partner to Streamline Multi-Omics Research with AI-Enabled Integration
Sapio Sciences and Ultima Genomics have partnered to integrate Sapio’s AI-powered lab informatics platform with Ultima’s low-cost, high-throughput sequencing technology. This collaboration aims to...
Merck Exits UK Research – Halts £1.3 Billion London Lab Plans
Merck has abandoned its major £1.3 billion research center project in London and discontinued all discovery research operations in the UK due to dissatisfaction with the local pharmaceutical...
Capsida Pauses Gene Therapy Trial After Patient Death
Capsida Biotherapeutics has paused its phase I/II trial of a gene therapy for STXBP1 encephalopathy following the death of the first treated pediatric patient. The experimental viral vector...
LB Pharmaceuticals Raises $285 Million in Major Biotech IPO
LB Pharmaceuticals completed a $285 million Nasdaq debut, the largest biotech IPO so far in 2025, ending a seven-month dry spell for sizable listings. The company aims to finance late-stage trials...
Revolution Medicines Advances RAS Blocker to Phase III for Pancreatic Cancer
Revolution Medicines announced plans to initiate a global, randomized phase III trial of its RAS inhibitor daraxonrasib as first-line treatment for metastatic pancreatic ductal adenocarcinoma,...
CRISPR-Cas9 Base Editing Shows Promise Against Rare Vascular Disease
Researchers at Massachusetts General Brigham have engineered a bespoke CRISPR-Cas9 base editor to precisely correct the ACTA2 mutation causing multisystemic smooth muscle dysfunction syndrome...
Small Cell Lung Cancer Forms Functional Brain Synapses to Promote Growth
Groundbreaking studies reveal that small cell lung cancer (SCLC) cells establish bona fide synaptic connections with neurons in the brain microenvironment, creating electrical signaling pathways...
Johnson & Johnson Gains FDA Approval for Novel Bladder Cancer Drug-Device
Johnson & Johnson received FDA clearance for Inlexzo, an intravesical gemcitabine-releasing device targeting Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. The therapy...
Novo Nordisk Restructures – Cutting 11% Workforce Amid Market Challenges
Novo Nordisk announced plans to cut 9,000 jobs, approximately 11% of its workforce, as part of a major restructuring under new CEO Mike Doustdar aimed at improving agility amid increased...
Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research
Sapio Sciences and Ultima Genomics have entered a strategic partnership to integrate Sapio’s AI-powered lab informatics platform with Ultima’s high-throughput, low-cost sequencing technologies....
Innovative AI Approaches Transforming Clinical Decision Support at Point of Care
The clinical decision support market is rapidly evolving, driven by heavy investor funding and diverse strategies emphasizing specialization, deep data integration, and broad distribution...
LB Pharma Boosts IPO, Secures $285M for Schizophrenia Drug Trials
LB Pharmaceuticals successfully raised $285 million in its Nasdaq initial public offering, the largest biotech IPO so far this year. The capital will fund Phase 3 trials of LB-102, a modified...
J&J Wins FDA Nod for Bladder Cancer Drug-Device Combo Inlexzo
Johnson & Johnson secured FDA approval for Inlexzo, an intravesical gemcitabine-releasing device for non-muscle invasive bladder cancer patients unresponsive to BCG immunotherapy. The system...
Small Cell Lung Cancer Cells Form Neural Synapses Driving Tumor Growth
Cutting-edge studies have revealed that small cell lung cancer (SCLC) cells establish functional, synapse-like connections with neurons both in the lung and brain metastases. These...